{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T22:27:33Z","timestamp":1717108053148},"reference-count":22,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2005,1,11]],"date-time":"2005-01-11T00:00:00Z","timestamp":1105401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2005,5,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This pilot study was carried out to gain a first insight into the effects of peptide vaccination in melanoma patients in the high\u2010risk adjuvant disease setting. From the adjuvant peptide vaccination studies carried out in our institution since 1998, we identified all melanoma patients with a history of at least 3 completely resected metastases during the year preceding enrollment into the trial and describe the clinical and immunologic observations. Out of a total of 44 patients with resected cutaneous melanoma entered into adjuvant peptide vaccination trials, 9 patients were identified with more than 3 metastases in the year before vaccination. After initiation of vaccination, 2 patients remained relapse\u2010free for 27 and 42+ months, 2 patients experienced single or several initial relapses and subsequent relapse\u2010free intervals of 18 and 65+ months, whereas 5 patients progressed. In both patients with relapse after prolonged relapse\u2010free intervals, the relapses were initially confined to the small intestine and could be resected. Induction or boosting of functional tyrosinase peptide\u2010specific T cells was noted in 6 of 8 patients, including all 4 patients with prolonged relapse\u2010free intervals. In conclusion, adjuvant peptide vaccination was associated with cessation of recurrences in 4 of 9 patients, of whom all 4 had an immunologic response to the vaccine. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ijc.20819","type":"journal-article","created":{"date-parts":[[2005,1,11]],"date-time":"2005-01-11T23:46:57Z","timestamp":1105487217000},"page":"936-941","source":"Crossref","is-referenced-by-count":10,"title":["Peptide vaccination after repeated resection of metastases can induce a prolonged relapse\u2010free interval in melanoma patients"],"prefix":"10.1002","volume":"114","author":[{"given":"Anne","family":"Letsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Keilholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fluck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Nagorsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Marie","family":"Asemissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Schmittel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eckhard","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Scheibenbogen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,1,11]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620000169"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19960703)67:1<54::AID-IJC11>3.0.CO;2-C"},{"key":"e_1_2_5_5_2","first-page":"37","article-title":"Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART\u20101\/melan A","volume":"3","author":"Cormier JN","year":"1996","journal-title":"Cancer J Sci Am"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0398-321"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000801)87:3<391::AID-IJC13>3.0.CO;2-K"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200003000-00012"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11045"},{"key":"e_1_2_5_10_2","first-page":"2756","article-title":"Phase I trial of a MART\u20101 peptide vaccine with incomplete Freund's adjuvant for resected high\u2010risk melanoma","volume":"5","author":"Wang F","year":"1999","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_11_2","first-page":"3012","article-title":"Phase I trial of a melanoma vaccine with gp100 280\u2013288 peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcome","volume":"7","author":"Slingluff CL","year":"2001","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3836"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10328"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10961"},{"key":"e_1_2_5_15_2","first-page":"5582","article-title":"Bone marrow contains melanoma\u2010reactive CD8+ effector T cells and, compared with peripheral blood, enriched numbers of melanoma\u2010reactive CD8+ memory T cells","volume":"63","author":"Letsch A","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10961"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20000901)87:5<659::AID-IJC7>3.0.CO;2-7"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.33076"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0163"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(94)90122-8"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2579"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2004.22315.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.8.4875"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.20819","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.20819","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T04:30:15Z","timestamp":1696912215000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.20819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,5,10]]}},"alternative-id":["10.1002\/ijc.20819"],"URL":"https:\/\/doi.org\/10.1002\/ijc.20819","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,11]]}}}